Brynjolfur Thor Gylfason joins Akthelia as Financial controller

Icelandic biotech R&D company Akthelia Pharmaceuticals has appointed Brynjólfur Þór Gylfason as Financial Controller. Gylfason brings more than twenty years of financial leadership experience across the biotechnology and healthcare sectors, investment management, and advisory services.

He joins Akthelia from GS Holdings Group. He has also held roles at Danforth Advisors, WuXi NextCODE, Virðing hf., and Deloitte. Gylfason holds a Cand. Oecon. degree in Auditing from the University of Iceland and a BS in Business Administration from Reykjavik University.

Managing Akthelia Growth

Akthelia is growing fast and and bringing Gylfason aboard is an important step towards managing that responsibly" said Egill Másson, CEO of Akthelia Pharmaceuticals.

Akthelia Pharmaceuticals is an Icelandic biotech R&D company developing novel therapies that protect the mucosal lining of the gastrointestinal tract from injury and complications associated with chemotherapy and stem-cell treatments. The goal is to reduce or prevent patient discomfort, inflammation, and infections resulting from such therapies, ultimately improving quality of life, and increasing the likelihood of successful cancer treatment outcomes.